Literature DB >> 16232018

beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease.

Mitchell J Barnett1, Gary Milavetz, Peter J Kaboli.   

Abstract

STUDY
OBJECTIVES: To determine whether an association exists between health care resource use and beta-blocker therapy in patients with asthma or chronic obstructive pulmonary disease (COPD), and to determine whether any significant differences exist between type of beta-blocker agent administered and resource use.
DESIGN: Retrospective cohort study. DATA SOURCE: Three Veterans Administration (VA) databases with information from hospitals and clinics in Iowa and Nebraska. Patients. A total of 8390 veterans with a diagnosis of asthma or COPD receiving treatment with a beta-blocker or another cardiovascular agent.
MEASUREMENTS AND MAIN RESULTS: Clinic visits and hospital admissions for asthma or COPD that occurred in 2000-2001 were identified using electronic administrative data files. Analyses were adjusted for comorbidity and patient demographics. Mean patient age was 67 years, and 97% of the patients were men. In unadjusted analyses, patients taking beta-blockers had more hospital admissions, similar inpatient length of stay (LOS), and fewer outpatient clinic visits for asthma or COPD. In adjusted analyses, however, no difference was noted in the odds of hospital admission or in LOS, and patients had fewer clinic visits related to asthma or COPD. The hazard ratio for hospital admission for asthma or COPD during the observation year was similar for patients taking and not taking beta-blockers, and no difference was noted with selective versus nonselective beta-blockers. However, the hospital admission rate was lower with atenolol than metoprolol.
CONCLUSION: Patients taking beta-blockers did not have more hospital admissions or clinic visits for their asthma or COPD than patients not taking these agents. When clinically indicated, beta-blockers-especially atenolol-should be considered for patients with asthma or COPD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16232018     DOI: 10.1592/phco.2005.25.11.1550

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  [Medical therapy of heart and lung diseases. Effects on the respective other organ].

Authors:  S Möhlenkamp; G Weinreich; T Neumann; T Voshaar; H Teschler
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

Review 2.  Hemokinins and endokinins.

Authors:  N M Page
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

Review 3.  Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure.

Authors:  Steve Tsai; Marc Klapholz
Journal:  Curr Heart Fail Rep       Date:  2007-06

Review 4.  Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues.

Authors:  Miranda R Andrus; Joyce V Loyed
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.

Authors:  Kuo-Yang Huang; Ping-Tao Tseng; Yi-Cheng Wu; Yu-Kang Tu; Brendon Stubbs; Kuan-Pin Su; Yutaka J Matsuoka; Chih-Wei Hsu; Ching-Hsiung Lin; Yen-Wen Chen; Pao-Yen Lin
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

Review 6.  The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports.

Authors:  Miriam Bennett; Catherina L Chang; Michael Tatley; Ruth Savage; Robert J Hancox
Journal:  ERJ Open Res       Date:  2021-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.